<DOC>
	<DOCNO>NCT02300610</DOCNO>
	<brief_summary>The main purpose study find dose enzalutamide safely give gemcitabine cisplatin patient advanced bladder cancer . Researchers also want find side effect drug give together . This study also help find effect tumor combination enzalutamide , gemcitabine cisplatin .</brief_summary>
	<brief_title>Enzalutamide Combination With Gemcitabine Cisplatin Bladder Cancer</brief_title>
	<detailed_description>For phase 1 dose escalation phase , start dose enzalutamide 80 mg orally day ( Level 1 ) . The dose regimen cisplatin gemcitabine standard dos Gemcitabine 1000 mg/m^2 IV day 1 , 8 cisplatin 70 mg/m2 IV day 1 , repeat every 21 day total 6 cycle . Three patient treat dose level 1 ( enzalutamide 80 mg daily ) . If 0 patient experience dose limit toxicity ( DLT ) , dose escalation do level 2 enzalutamide 160 mg daily . If 1 patient experience DLT , 3 patient treat dose level ; 1 6 experience DLT , escalate dose next level , 2 6 experience DLT , dose level 1 ( 80 mg enzalutamide ) recommend dose dose expansion cohort . The cohort expansion do enrol 12 patient stage IV bladder cancer , express androgen receptor ( AR ) stain 1+ immunohistochemistry ( IHC ) , determine safety tolerability cisplatin gemcitabine recommend dose level enzalutamide ( 80 mg 160 mg , depend upon safety result dose escalation part ) expand cohort patient AR + bladder cancer . Enzalutamide would continue completion 6 cycle gemcitabine-cisplatin patient exhibit response stable disease , experience disease progression .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Cytologically histologically confirm evidence transitional cell carcinoma bladder , renal pelvis , ureter urethra . Patients Stage IV ( locally advance metastatic ) disease . Must measurable disease , per Response Evaluation Criteria Solid Tumors ( RECIST ) . Minimum 4 week since major surgery , completion radiation . Prior treatment cytotoxic chemotherapy requirement , allow use neoadjuvant , adjuvant bladder preserving protocol , long administer &gt; 6 month prior start study . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Life expectancy 12 week . Must normal organ marrow function . Women childbearing potential must negative serum urine pregnancy test within 14 day administration first study treatment . Women must lactate . Sexually active woman childbearing age men willing follow birth control guideline . Should able swallow enzalutamide comply study requirement . Prior treatment cytotoxic chemotherapy metastatic setting . Prior treatment cytotoxic chemotherapy allow use neoadjuvant , adjuvant bladder preserving protocol , long administer &gt; 6 month prior start study . Have undergone major surgery within 4 week prior study enrollment . Chronic treatment steroid immunosuppressant drug . Should receive immunization attenuate live vaccine study period within 1 week study entry . History seizure , predispose factor seizure , include underlie brain injury loss consciousness within previous 12 month , transient ischemic attack within previous 12 month , cerebral vascular accident brain arteriovenous malformation . Untreated brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . Congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , ventricular fibrillation , clinically significant bradycardia , advanced heart block history acute myocardial infarction within 6 month precede enrollment . Known history HIV . Have severe and/or uncontrolled medical condition condition could affect participation study . Women pregnant breast feeding , women/men able conceive unwilling practice birth control guideline . Concurrent medication strongly inhibit induce CYP enzyme ( gemfibrozil , Rifampin , carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , rifapentine , bosentan , efavirenz , etravirine , modafinil , nafcillin , St. John 's Wort ) . History stage III great cancer , except basal squamous cell skin cancer adequately treat stage I II cancer adequately treat diseasefree ≥ 2 year . Incidental findings stage I II prostate cancer consider cure radical cystoprostatectomy allow . Prior use enzalutamide . Radiation therapy via external beam brachytherapy within 28 day registration . Patients ineligible receive cisplatin : Creatinine clearance le 60 mL/minute , hear loss 25 decibel ( dB ) 2 contiguous frequency , grade 2 high peripheral neuropathy , New York Heart Association Class III high heart failure . Allergy/sensitivity study drug ( gemcitabine , cisplatin , enzalutamide ) , drug chemically relate study drug , excipients . Brain metastasis ( include treat stable brain metastasis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ureteral Diseases</keyword>
	<keyword>Urinary Bladder Diseases</keyword>
	<keyword>Transitional Cell Carcinoma</keyword>
	<keyword>Bladder</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Renal</keyword>
	<keyword>Pelvis</keyword>
	<keyword>Ureter</keyword>
	<keyword>Urethra</keyword>
</DOC>